Wegovy and Rosuvastatin Interaction: What Women Need to Know

How Wegovy and Rosuvastatin Work in the Body

These two drugs travel almost entirely different metabolic routes, which is the main reason their combination does not carry a high-alert interaction flag in clinical DDI databases such as Lexicomp or Micromedex.

Semaglutide pharmacokinetics

Semaglutide 2.4 mg (Wegovy) is a GLP-1 receptor agonist injected subcutaneously once weekly. It is not metabolized by cytochrome P450 enzymes. According to the Wegovy US prescribing information, semaglutide is proteolytically cleaved in plasma and tissues, and the fatty-acid side chain that prolongs its half-life is albumin-bound, not CYP-dependent. It does not inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein at clinically relevant concentrations.

The one mechanism worth tracking is gastric emptying. Semaglutide slows gastric emptying, particularly in the first hours after a dose, and the Novo Nordisk phase 1 DDI study showed that a single oral drug given simultaneously with semaglutide could see its Cmax delayed by up to 11 percent and AUC essentially unchanged. That means the rate of rosuvastatin absorption may slow, but the total amount absorbed stays the same.

Rosuvastatin pharmacokinetics

Rosuvastatin belongs to the HMG-CoA reductase inhibitor class. Unlike atorvastatin or simvastatin, it undergoes minimal CYP2C9 metabolism and is instead taken up into hepatocytes primarily by OATP1B1 and OATP1B3 transporters, then partially excreted unchanged. Because neither semaglutide nor any known pharmacodynamic effect of GLP-1 receptor agonism alters OATP1B1 activity, the hepatic uptake of rosuvastatin is not meaningfully changed by Wegovy.

This matters clinically. The drugs that do raise rosuvastatin plasma levels dangerously, such as cyclosporine (8-fold increase) or certain antivirals, do so by blocking OATP1B1. Semaglutide does not touch that transporter.

What the Clinical Evidence Actually Shows

No randomized controlled trial has examined the Wegovy-rosuvastatin combination as its primary endpoint. This is an evidence gap women deserve to know about. What exists is a body of indirect evidence from GLP-1 agonist drug interaction studies, statin pharmacology literature, and post-marketing pharmacovigilance.

The SUSTAIN and STEP trial lipid data

The STEP 1 trial enrolled 1,961 adults with obesity or overweight plus comorbidity and found that semaglutide 2.4 mg reduced LDL-C by approximately 3 to 4 percent and triglycerides by 18 percent versus placebo at 68 weeks. A significant proportion of STEP participants were already on statins at baseline, and no excess myopathy signal was observed in that subgroup in the published safety data.

In the earlier SUSTAIN 6 cardiovascular outcomes trial using semaglutide 1 mg, 3,297 patients with type 2 diabetes were randomized, with roughly 60 percent on a statin at baseline. Again, no interaction-specific adverse event was flagged for rosuvastatin users.

The gastric-emptying question

A dedicated pharmacokinetic study published in Clinical Pharmacokinetics tested oral medications co-administered with once-weekly semaglutide 1 mg in healthy volunteers. Investigators found that mean Cmax of the co-administered drugs fell by 7 to 11 percent and median Tmax was delayed by roughly 30 to 60 minutes, while AUC was unchanged. Because rosuvastatin is taken once daily and its LDL-lowering effect correlates with AUC rather than peak concentration, a Cmax delay is not expected to reduce clinical efficacy.

The practical guidance: if you take rosuvastatin in the morning, you do not need to reshuffle your schedule around your weekly Wegovy injection. The AUC stays intact.

A useful way to think about this interaction is a three-tier framework specific to women:

Tier 1: No action needed applies to most women on stable rosuvastatin doses below 20 mg who are starting Wegovy for weight management, have no muscle symptoms, and have normal baseline creatine kinase (CK) and liver function.

Tier 2: Monitor closely applies to women on rosuvastatin 40 mg, women with hypothyroidism (which itself raises myopathy risk), women in perimenopause or early post-menopause whose lipid trajectory is changing rapidly, and women with PCOS taking multiple metabolic agents.

Tier 3: Specialist review before combining applies to women with a personal or family history of statin-induced myopathy, CK elevation at baseline, severe renal impairment (rosuvastatin accumulates at eGFR <30), or active liver disease.

Muscle Risk: The Signal That Matters Most

The most clinically meaningful concern when any statin is part of a multi-drug regimen is myopathy, ranging from myalgia to the rare but serious rhabdomyolysis. Rosuvastatin carries this class-wide risk, and women have specific vulnerability.

Why women are at higher muscle risk on statins

Women are 1.5 to 2 times more likely to report statin-associated muscle symptoms (SAMS) than men, based on observational data from the PRIMO study of 7,924 statin users in France. The mechanisms are not fully established, but lower muscle mass per unit body weight, differences in drug distribution volume, and the modulatory effect of estrogen on muscle fiber composition are all proposed contributors.

Post-menopausal women on rosuvastatin represent a particularly important group. After estrogen loss, LDL tends to rise, statin doses are often increased, and the protective effects of estrogen on muscle may be diminished. If you are peri- or post-menopausal and your clinician is adjusting your rosuvastatin dose at the same time you are starting Wegovy, ask for a baseline CK measurement before escalating.

Hypothyroidism and the compounded risk

Hypothyroidism, which affects approximately 5 percent of US women and is more common in women with PCOS and Hashimoto thyroiditis, independently raises the risk of statin myopathy. The rosuvastatin prescribing information specifically lists hypothyroidism as a predisposing factor for myopathy. Women starting Wegovy who also have untreated or undertreated hypothyroidism need thyroid optimization before dose escalation of either drug.

What to watch for

Report any of the following to your prescriber promptly:

• New or worsening muscle pain, tenderness, or weakness
• Cola- or tea-colored urine (a sign of myoglobinuria)
• Muscle cramps that wake you at night and are new since starting either drug
• Unusual fatigue in the legs during normal activity

Rhabdomyolysis is rare, with an estimated incidence of less than 0.1 percent across statin users, but the consequences are severe enough to treat any new muscle symptoms as urgent until proven otherwise.

Women-Specific Conditions That Change the Picture

PCOS

Polycystic ovary syndrome affects 6 to 12 percent of reproductive-age women and is the single most common endocrine disorder in that group. Women with PCOS carry a disproportionately high cardiovascular risk profile: elevated LDL, elevated triglycerides, insulin resistance, and often central adiposity. This means many women with PCOS end up needing both a GLP-1 agonist and a statin.

GLP-1 receptor agonists including semaglutide have shown benefit in PCOS beyond weight loss. A 2022 systematic review in Fertility and Sterility found that GLP-1 agonists improved menstrual regularity, androgen levels, and insulin sensitivity in women with PCOS. When rosuvastatin is added for lipid control in the same patient, the combination is clinically rational and does not require special dose adjustment based on pharmacokinetics alone.

If you have PCOS and are on both drugs, your lipid panel may improve faster than expected on Wegovy (through weight loss) even before rosuvastatin's full effect is seen. Revisit whether the statin dose needs adjustment at the 3-month mark.

Perimenopause and post-menopause

The menopausal transition brings a predictable and often rapid shift in lipid metabolism. Estrogen normally suppresses LDL-receptor degradation and upregulates hepatic LDL clearance; when estrogen falls, LDL and lipoprotein(a) rise. A 2021 analysis in Menopause found that LDL-C increased by an average of 10 to 14 mg/dL in the two years surrounding the final menstrual period, independent of weight change.

Women who are starting Wegovy for weight management in the perimenopausal years may simultaneously need to initiate or intensify rosuvastatin. The interaction profile remains the same as described above, but the monitoring context is different: weight loss from Wegovy can improve LDL by 3 to 8 percent on its own through reduced hepatic fat and improved insulin sensitivity, so your statin dose may actually be able to come down over 6 to 12 months.

Female pattern metabolic disease

Women with metabolic syndrome tend to store visceral fat differently from men, and cardiovascular risk in women is underestimated by standard calculators built on male-dominant trial populations. The combination of Wegovy and rosuvastatin in a woman with high-risk metabolic profile addresses two separate pathways: GLP-1 agonism reduces body weight, hepatic steatosis, and systemic inflammation, while rosuvastatin directly blocks cholesterol synthesis. These are complementary rather than overlapping mechanisms.

Pregnancy, Lactation, and Contraception: Required Reading

Both Wegovy and rosuvastatin are contraindicated in pregnancy. This is not a nuance. It is a hard stop.

Wegovy in pregnancy

The Wegovy prescribing label states that semaglutide caused fetal harm in animal studies at doses below human exposure levels. Human data are limited. The FDA advises discontinuing Wegovy at least 2 months before a planned pregnancy, because the drug's long half-life means it persists in the body for approximately 5 weeks after the last dose, and a 2-month washout provides adequate clearance.

If you become pregnant while on Wegovy, stop the drug immediately and contact your obstetric provider. Enrollment in the pregnancy exposure registry can be reached through Novo Nordisk at 1-800-727-6500.

Rosuvastatin in pregnancy

Rosuvastatin is formally contraindicated in pregnancy. Statins inhibit cholesterol synthesis, and cholesterol is essential for fetal development, including steroid hormone production and cell membrane formation. The rosuvastatin label classifies it as contraindicated (previously FDA Category X) and advises stopping the drug as soon as pregnancy is recognized.

Lactation

Semaglutide: no adequate human data exist on transfer into breast milk. Animal data show low transfer, but given the drug's molecular weight and the absence of human safety data, Wegovy is not recommended during breastfeeding.

Rosuvastatin: small amounts transfer into breast milk. Because of the potential for serious adverse reactions in a nursing infant, the rosuvastatin label advises against use during breastfeeding.

Contraception counseling for women on both drugs

If you are of reproductive age and taking both Wegovy and rosuvastatin, reliable contraception is essential. Women on oral contraceptive pills who start Wegovy should be aware that delayed gastric emptying may theoretically reduce the rate (though not the overall extent) of OCP absorption, as the same pharmacokinetic study referenced earlier showed. No clinical pregnancy failures have been attributed to this mechanism in published data, but switching to a non-oral contraceptive (IUD, implant, patch, or ring) eliminates this theoretical concern entirely for women seeking maximal contraceptive reliability.

Who This Combination Is Right For (and Who Should Pause)

Good candidates for Wegovy plus rosuvastatin

• Women with obesity or overweight plus dyslipidemia who have not reached LDL goals on lifestyle alone
• Women with PCOS and mixed metabolic risk
• Post-menopausal women with rising LDL and weight gain since menopause
• Women with type 2 diabetes and cardiovascular risk who need both glucose/weight management and lipid control
• Women who have tolerated rosuvastatin for more than 6 months without muscle symptoms

Women who need additional evaluation first

• Women planning pregnancy within the next 3 to 6 months (stop both drugs with appropriate lead time)
• Women with active or suspected liver disease (rosuvastatin is hepatically metabolized in part; Wegovy can cause mild transaminase elevation)
• Women with severe renal impairment (eGFR <30 mL/min/1.73 m²): rosuvastatin should not exceed 10 mg in this group per its FDA label
• Women with a personal history of statin-induced myopathy or CK elevation greater than 10 times the upper limit of normal
• Women on medications that strongly inhibit OATP1B1 (cyclosporine, certain HIV antivirals), as those drugs would raise rosuvastatin levels regardless of Wegovy

Drug Interaction Databases: What They Say and Why

Major DDI databases categorize the Wegovy-rosuvastatin combination differently based on methodology:

Lexicomp: No interaction listed between semaglutide and rosuvastatin as of the most recent update.

Micromedex: No contraindication or major interaction flag. The gastric-emptying effect of GLP-1 agonists is noted as a class-wide minor concern for time-sensitive oral medications.

FDA label cross-reference: Neither the Wegovy label nor the rosuvastatin label names the other drug in its drug interaction section. This absence of a listed interaction is clinically meaningful, not an oversight.

The American College of Cardiology and American Heart Association 2019 cholesterol guideline, endorsed by the AHA, does not flag GLP-1 agonists as a contraindication or caution for any statin class, including rosuvastatin.

Monitoring Plan for Women on Both Drugs

A practical schedule based on current guideline standards:

Before starting Wegovy (if already on rosuvastatin):

• Confirm current CK level (rule out subclinical myopathy)
• Fasting lipid panel (baseline for tracking GLP-1-driven lipid improvement)
• Complete metabolic panel including hepatic enzymes

At 3 months:

• Repeat fasting lipid panel. Women on Wegovy often see LDL fall modestly from weight loss; your clinician may consider whether to maintain or reduce the rosuvastatin dose
• Ask about muscle symptoms at every visit, not just when you volunteer them

At 6 months:

• Reassess cardiovascular risk using a validated tool (ASCVD Pooled Cohort Equation)
• For perimenopausal women: assess whether hormonal changes are affecting the lipid trajectory

Annually:

• Full metabolic and lipid reassessment
• Thyroid function, particularly in women with PCOS or autoimmune thyroid history

"Clinicians should consider that GLP-1 receptor agonists independently improve cardiometabolic risk factors including LDL and triglycerides, and this may allow for statin dose de-escalation in some patients after 6 to 12 months of therapy," according to a 2023 joint position statement from the American Diabetes Association and the European Association for the Study of Diabetes.

A Note on Evidence Gaps for Women

Most pharmacokinetic interaction studies, including the semaglutide DDI study cited above, enrolled predominantly male or mixed-sex populations with insufficient stratification by hormonal status. Women's drug absorption, distribution, and clearance change meaningfully across the menstrual cycle (gastric motility is slower in the luteal phase), with use of hormonal contraceptives, during perimenopause, and with postmenopausal hormone therapy.

This means the gastric-emptying delay observed in the DDI study may be modestly larger in women during the luteal phase, and potentially smaller in post-menopausal women not on hormone therapy. No trial has directly measured this. Until sex-stratified pharmacokinetic data exist, the best clinical approach is to take rosuvastatin at a consistent time each day, monitor symptoms, and report any change in lipid control to your provider.

"Women have been historically under-represented in pharmacokinetic and drug interaction studies, and extrapolating male-dominant data to women across hormonal life stages requires explicit clinical caution," as articulated in ACOG Committee Opinion 646, available at ACOG.org.